SPY328.73+5.23 1.62%
DIA271.70+3.60 1.34%
IXIC10,913.56+241.30 2.26%

Fulgent Genetics Reports Addition Of Influenza A, B To All Coronavirus Tests

Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent Genetics" or the "company"), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced

· 09/03/2020 06:05

Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent Genetics" or the "company"), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that beginning September 28th, all patients tested for COVID-19 by Fulgent Genetics will also receive results for Influenzas A and B.
 

"With flu season fast approaching, we believe it will be critical to differentiate between Influenza and SARS-CoV-2, and that this combination of virus testing will become the standard of care during the remainder of the pandemic. Adding Influenza A and B testing to our COVID-19 testing solution further solidifies Fulgent Genetics as the go-to laboratory for testing during this pandemic, as it has become increasing clear that RT-PCR is the gold standard for COVID-19 testing," commented Brandon Perthuis, Chief Commercial Officer of Fulgent Genetics. "While some non-RT-PCR tests have the potential to deliver faster results, the sensitivity and specificity of our RT-PCR test for COVID-19, especially at low-level viral loads, is critical to minimize both false positives and false negatives. We believe RT-PCR testing solutions are currently the most viable solution for asymptomatic testing, early detection after potential exposure and for preventative screening. Finally, while some labs have difficulty delivering results within their projected turn-around-times for RT-PCR tests, Fulgent has consistently delivered RT-PCR testing results within 24 hours from receipt of sample," Perthuis added.

The addition of Influenza A and B testing will apply to all Fulgent COVID-19 tests and platforms including drive-through testing, enterprise testing for back-to-work and back-to-school, facility-based testing, as well as its FDA authorized Picture at-home test.